Shuttle Pharmaceuticals | 8-K: Current report
Shuttle Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Officer Lorber Timothy J.
Shuttle Pharmaceuticals | ARS: Annual Report to Security Holders
Shuttle Pharmaceuticals | DEF 14A: Definitive information statements
Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer Current CFO, Michael Vander Hoek, transitions to full-time Vice President, Regulatory
Shuttle Pharmaceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Shuttle Pharmaceuticals | 8-K: Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
Shuttle Pharmaceuticals | 8-K: First Quarter 2024 Financial Results
Shuttle Pharmaceuticals | 10-Q: Quarterly report
Shuttle Pharmaceuticals | 8-K: Current report
Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
Shuttle Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933
Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Provides Fourth Quarter 2023 Corporate Update
Shuttle Pharmaceuticals | 424B3: Prospectus
Shuttle Pharmaceuticals | 10-K: Annual report
Shuttle Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Senanayake Chris
Shuttle Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Vander Hoek Michael
Shuttle Pharmaceuticals | 8-K: Shuttle Pharmicals Receives Notice of Nasdaq's Failure to Satisfy Continued Listing Rules and CEO Anatoly Dritschilo to Attend Emerging Growth Conference on March 6, 2024
Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
Shuttle Pharmaceuticals | 8-K: Asset Purchase Agreement
No Data